132,142 Shares in Biogen Inc. $BIIB Bought by Ieq Capital LLC

Ieq Capital LLC bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 132,142 shares of the biotechnology company’s stock, valued at approximately $28,551,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Rothschild Investment LLC lifted its holdings in shares of Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in shares of Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after buying an additional 57 shares in the last quarter. Kera Capital Partners Inc. raised its position in Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 58 shares during the last quarter. Parallel Advisors LLC raised its position in Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after buying an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 66 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on BIIB shares. Rothschild & Co Redburn upped their price target on Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Mizuho lifted their price objective on shares of Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Oppenheimer reissued an “outperform” rating and issued a $300.00 price objective on shares of Biogen in a research report on Wednesday, July 29th. Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Biogen in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and a consensus target price of $227.07.

Biogen Stock Performance

BIIB opened at $216.78 on Friday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $222.15. The business has a 50 day moving average of $205.53 and a 200-day moving average of $194.48. The stock has a market cap of $32.03 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 6.68 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the previous year, the firm earned $5.47 EPS. The firm’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities research analysts expect that Biogen Inc. will post 12.39 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.